



ASX Announcement
12 March 2020

LITTLE GREEN PHARMA GRANTED EXPANDED MEDICINAL CANNABIS LICENCE AND NEW MANUFACTURING LICENCE

Highlights:

- **Little Green Pharma granted expanded Medicinal Cannabis Licence and new Manufacturing Licence**
 - Expanded Medicinal Cannabis Licence covers LGP's expanded cultivation facility
 - Manufacturing Licence covers LGP's new manufacturing facility at which the Company intends to produce cannabis extracts for manufacture into final product form
- **Licences are an important step in expanding LGP's cultivation and manufacturing capacity and fulfilling purchase agreements in Germany and the UK**

Little Green Pharma Ltd (ASX: LGP) ("LGP" or the "Company") is pleased to announce that the Office of Drug Control ("ODC") has granted the Company an expansion to LGP's current Medicinal Cannabis Licence to allow the cultivation and production of medicinal cannabis, and conduct ancillary activities, at its expanded cultivation facility and adjacent new manufacturing facility in Western Australia.

The Company has also been granted a Manufacturing Licence by the ODC to manufacture cannabis dry flower, extracts, tinctures, and resins at its new manufacturing facility.

Subject to the granting of an expanded Medicinal Cannabis Permit, LGP expects first planting at its expanded cultivation facility to take place in Q2CY2020.

The expanded cultivation facility will consist of nine flowering rooms. At full capacity the cultivation facility will have the capacity to produce sufficient cannabis flower to manufacture more than 110,000 bottles of medicinal cannabis oil per annum.

Commenting on the granting of the licences, LGP Managing Director Fleta Solomon said, *"These licences mark an important step in expanding LGP's cultivation and manufacturing capacity and achieving internal vertical integration and cost reduction."*

"The expanded Medicinal Cannabis Licence and new Manufacturing Licence will give us greater production flexibility and the capacity to fulfil recently signed purchase agreements with distributors in Germany and the UK."

ENDS

For interviews, export updates, clinical study protocols and patient case studies please contact:

David Tasker
Chapter One Advisors

E: dtasker@chapteroneadvisors.com.au

M: +61 433 112 936

Celia Young, Marketing Manager
Little Green Pharma

E: celia@lgpharma.com.au

M: +61 421 730 885

For more information about Little Green Pharma go to: www.littlegreenpharma.com



BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Craig Basson".

Craig Basson
Company Secretary

